MPM BioImpact holds 1.4% of Context Therapeutics

Rhea-AI Filing Summary

MPM BioImpact LLC filed Amendment No. 2 to a Schedule 13G reporting its beneficial ownership of common stock of Context Therapeutics Inc. As of June 30, 2026, MPM BioImpact reports beneficial ownership of 1,299,046 shares of Context Therapeutics common stock, representing 1.4% of the outstanding class. The firm has sole voting and sole dispositive power over all of these shares, with no shared voting or dispositive power reported. The filing also indicates that MPM BioImpact’s holdings are now 5 percent or less of this class of securities.

Key Figures

Shares beneficially owned: 1,299,046 shares Percent of class: 1.4% Sole voting power: 1,299,046 shares +1 more

4 metrics

Shares beneficially owned 1,299,046 shares Common stock of Context Therapeutics beneficially owned by MPM BioImpact LLC

Percent of class 1.4% Percentage of Context Therapeutics common stock class owned by MPM BioImpact LLC

Sole voting power 1,299,046 shares Shares over which MPM BioImpact LLC has sole power to vote or direct the vote

Sole dispositive power 1,299,046 shares Shares over which MPM BioImpact LLC has sole power to dispose or direct disposition

Key Terms

beneficially owned, sole voting power, sole dispositive power, Ownership of 5 percent or less of a class

4 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 1,299,046"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"(i) Sole power to vote or to direct the vote: 1,299,046"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"(iii) Sole power to dispose or to direct the disposition of: 1,299,046"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Ownership of 5 percent or less of a class financial

"Item 5. | Ownership of 5 Percent or Less of a Class."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Context Therapeutics (CNTX) does MPM BioImpact LLC currently own?

MPM BioImpact LLC reports owning 1.4% of Context Therapeutics’ common stock. This corresponds to 1,299,046 shares as disclosed in Amendment No. 2 to its Schedule 13G filing.

How many Context Therapeutics (CNTX) shares does MPM BioImpact LLC beneficially own?

MPM BioImpact LLC beneficially owns 1,299,046 shares of Context Therapeutics common stock. This stake represents 1.4% of the company’s outstanding common stock according to the Schedule 13G/A.

Does MPM BioImpact LLC have sole or shared voting power over its CNTX shares?

MPM BioImpact LLC has sole voting power over 1,299,046 shares of Context Therapeutics. The filing reports no shared voting power and no shared dispositive power over any shares.

Is MPM BioImpact LLC still a 5% beneficial owner of Context Therapeutics (CNTX)?

No. MPM BioImpact LLC reports ownership of 5 percent or less of Context Therapeutics’ common stock. Its disclosed stake is 1.4%, below the 5% threshold for larger beneficial owners.

What class of Context Therapeutics (CNTX) securities is covered by MPM BioImpact’s Schedule 13G/A?

The filing covers common stock, par value $0.001 per share, of Context Therapeutics Inc. MPM BioImpact LLC reports beneficial ownership and voting and dispositive power for this class only.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:26 PM Accepted by SEC EDGAR 08/14/2026 - 04:03 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Context Therapeutics Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

21077P108

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 21077P108

1

Names of Reporting Persons

MPM BioImpact LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,299,046.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,299,046.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,299,046.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.4 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Context Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 2001 MARKET STREET, SUITE 3915 UNIT #15, PHILADELPHIA, PA, 19103.
Item 2.
(a)	Name of person filing: MPM BioImpact LLC
(b)	Address or principal business office or, if none, residence: 399 Boylston Street, Suite 1100 Boston, MA 02116
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 21077P108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,299,046
(b)	Percent of class: 1.4%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,299,046
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,299,046
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MPM BioImpact LLC

Signature:	Christopher Wolf
Name/Title:	Chief Financial Officer
Date:	08/14/2026